The New York Times Magazine published an article last week about the lesser-discussed ways selective serotonin reuptake inhibitors, such as fluoxetine and paroxetine, which are frequently prescribed to treat depression and anxiety, affect adolescents‘ sexual development. Post-SSRI sexual dysfunction is a condition in which sexual side effects from SSRIs (and serotonin and norepinephrine reuptake inhibitors) persist after [.].